Fumiya Yoneyama
Papers
1
Total Citations
5
H-Index
1
About
Dr. Fumiya Yoneyama is a leading urologic oncologist whose research focuses on optimizing surgical outcomes for patients with muscle-invasive bladder cancer (MIBC). His major contribution lies in critically evaluating the oncologic safety of robot-assisted radical cystectomy (RARC) compared to traditional open surgery. In a landmark multicenter retrospective study, Dr. Yoneyama investigated the incidence of peritoneal carcinomatosis and overall prognosis following RARC versus open radical cystectomy in a cohort of 429 patients. This work directly addresses a key clinical concern regarding the potential for cancer dissemination with minimally invasive techniques, providing real-world evidence to guide surgical decision-making. His findings have already garnered significant attention, accumulating 5 citations in a short period since 2025. By rigorously comparing these surgical approaches, Dr. Yoneyama is helping to refine best practices in bladder cancer surgery, ensuring that technological advancements do not compromise patient survival. His research is essential reading for urologic surgeons and oncologists seeking to balance the benefits of robotic surgery with the imperative of complete cancer control.
Research Focus
Key Achievements
Top Papers
- 1